Regentatlantic Capital LLC Raises Holdings in Johnson & Johnson (NYSE:JNJ)

Regentatlantic Capital LLC lifted its holdings in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 0.1% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 204,439 shares of the company’s stock after acquiring an additional 132 shares during the period. Johnson & Johnson makes up approximately 1.0% of Regentatlantic Capital LLC’s investment portfolio, making the stock its 18th largest holding. Regentatlantic Capital LLC’s holdings in Johnson & Johnson were worth $36,233,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Riversedge Advisors LLC boosted its position in Johnson & Johnson by 8.6% in the fourth quarter. Riversedge Advisors LLC now owns 3,664 shares of the company’s stock valued at $627,000 after buying an additional 289 shares during the last quarter. Andrew Hill Investment Advisors Inc. purchased a new stake in Johnson & Johnson in the fourth quarter valued at approximately $3,435,000. Ascent Wealth Partners LLC boosted its position in Johnson & Johnson by 2.3% in the fourth quarter. Ascent Wealth Partners LLC now owns 28,855 shares of the company’s stock valued at $4,936,000 after buying an additional 651 shares during the last quarter. PFG Private Wealth Management LLC purchased a new stake in Johnson & Johnson in the fourth quarter valued at approximately $99,000. Finally, First Merchants Corp boosted its position in Johnson & Johnson by 4.2% in the fourth quarter. First Merchants Corp now owns 59,341 shares of the company’s stock valued at $10,151,000 after buying an additional 2,383 shares during the last quarter. Hedge funds and other institutional investors own 68.78% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on JNJ shares. Credit Suisse Group upped their target price on Johnson & Johnson from $200.00 to $205.00 and gave the company an “outperform” rating in a research report on Wednesday, April 20th. Citigroup decreased their price target on Johnson & Johnson from $205.00 to $201.00 in a report on Wednesday, July 20th. Raymond James boosted their price target on Johnson & Johnson from $195.00 to $196.00 and gave the company an “outperform” rating in a report on Wednesday, April 20th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, May 17th. Finally, Morgan Stanley boosted their price target on Johnson & Johnson from $173.00 to $174.00 and gave the company an “equal weight” rating in a report on Friday, July 8th. Four analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $189.89.

Johnson & Johnson Trading Down 0.3 %

Shares of JNJ stock opened at $173.20 on Thursday. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.39 and a quick ratio of 1.14. The company has a market cap of $455.76 billion, a price-to-earnings ratio of 25.21, a PEG ratio of 3.28 and a beta of 0.63. The stock has a 50 day simple moving average of $175.99 and a 200-day simple moving average of $174.36. Johnson & Johnson has a 1-year low of $155.72 and a 1-year high of $186.69.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its quarterly earnings data on Tuesday, July 19th. The company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.57 by $0.02. Johnson & Johnson had a return on equity of 36.56% and a net margin of 19.21%. The firm had revenue of $24.02 billion during the quarter, compared to the consensus estimate of $23.85 billion. During the same period in the prior year, the company earned $2.48 EPS. The firm’s revenue was up 3.0% compared to the same quarter last year. On average, equities research analysts expect that Johnson & Johnson will post 10.05 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd will be paid a $1.13 dividend. This represents a $4.52 annualized dividend and a yield of 2.61%. The ex-dividend date of this dividend is Monday, August 22nd. Johnson & Johnson’s dividend payout ratio is currently 65.79%.

Insider Activity at Johnson & Johnson

In related news, EVP Kathryn E. Wengel sold 40,000 shares of the stock in a transaction on Friday, June 10th. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the transaction, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at approximately $12,336,803. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 40,000 shares of the company’s stock in a transaction on Friday, June 10th. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the sale, the executive vice president now directly owns 71,311 shares in the company, valued at approximately $12,336,803. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CAO Robert J. Decker sold 8,462 shares of the company’s stock in a transaction on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total value of $1,523,160.00. Following the completion of the sale, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at $2,785,140. The disclosure for this sale can be found here. 0.35% of the stock is owned by corporate insiders.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Recommended Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.